|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |
| --- |
| **Załącznik Nr 1 - Kosztorys ofertowy**  |
|  |  |  |  |
|  |  |  |  |
|   |  |  |  |
|  **Tabela A1** |  |  |  |
|  |  |  |  |
| **Przeciwciała /immunoreagenty/ monoklonalne i poliklonalne dla skrawków**  |
| **parafinowych w gotowych rozcieńczeniach i stężonych** |  |
| **do automatycznego, standaryzowanego oznaczania.** |  |

 |
| **LP** | **PRZECIWCIAŁO** | **CLON** | **Ilość testów** | **Cena jednostkowa brutto** | **Wartość brutto** | **Producent** | **Numer katalogowy i nazwa na fakturze** |
| 1 | Progesteron | Pgr 636 lub .1E2 | 1800 |  |  |  |  |
| 2 | Estrogen | SP 1 lub EP 1 | 1800 |  |  |  |  |
| 3 | Desmina | D 33 lub DE-R-11 | 100 |  |  |  |  |
| 4 | Vimentyna | .V9 | 240 |  |  |  |  |
| 5 | Melanosome (HMB-45) | HMB45 | 500 |  |  |  |  |
| 6 | CD – 45(lca) | 2B11&PD7/26 | 600 |  |  |  |  |
| 7 | Chromog. | LK2H10 lub Polyclonal | 120 |  |  |  |  |
| 8 | Ki – 67 | MIB-1lub 30-9 | 2000 |  |  |  |  |
| 9 | BCL 2 | 124 | 300 |  |  |  |  |
| 10 | SMA | 1A4 | 300 |  |  |  |  |
| 11 | CD3 | 2GV6 lub Polyklonal | 600 |  |  |  |  |
| 12 | CD20 | L26 | 600 |  |  |  |  |
| 13 | CD 30 | Ber-H2 | 200 |  |  |  |  |
| 14 | CD 34 | QBEnd10 | 450 |  |  |  |  |
| 15 | CK AE1/AE3 | AE1/AE3&PCK26 | 1800 |  |  |  |  |
| 16 | CK 20 | SP 33 lub Ks20.8 | 300 |  |  |  |  |
| 17 | CK 5/6 | D5/16B4  | 100 |  |  |  |  |
| 18 | S 100 | Polyclonal  | 500 |  |  |  |  |
| 19 | S-100 A | 4C4.9  | 120 |  |  |  |  |
| 20 | Calcitonina | Polyclonal | 100 |  |  |  |  |
| 21 | Calretynina | SP65 lub DAK-Calret 1 | 50 |  |  |  |  |
| 22 | Tyroglobulina | 2H11+6E1 lub Polyclonal | 100 |  |  |  |  |
| 23 | Melan A | A 103 | 100 |  |  |  |  |
| 24 | Ep CAM | Ber Ep 4  | 100 |  |  |  |  |
| 25 | CK 19 | A53-B/A2.26 lub RCK 108 | 150 |  |  |  |  |
| 26 | CK 7 | SP52 lub OV-TL12/30 | 400 |  |  |  |  |
| 27 | Cyklina D1 | SP4-R lub EP 12 | 250 |  |  |  |  |
| 28 | CD23 | SP23 DAK-CD23 | 300 |  |  |  |  |
| 29 | PLAP | NB10 lub 8A9 | 80 |  |  |  |  |
| 30 | Mammaglobina | 31A5 lub 304-1A5 | 80 |  |  |  |  |
| 31 | ALK | ALK-01 lub ALK1 | 80 |  |  |  |  |
| 32 | CD 5 | SP19 lub 4C7 | 300 |  |  |  |  |
| 33 | CD 10 | SP67 lub 56C6 | 400 |  |  |  |  |
| 34 | CD 117 c-kit | (9.7) | 200 |  |  |  |  |
| 35 | BCL 6 | GI191E/A8 lub PG-B6p | 250 |  |  |  |  |
| 36 | Myeloperoxidase | Polyclonal | 300 |  |  |  |  |
| 37 | E-cadheryna | 36 lub NCH-38 | 250 |  |  |  |  |
| 38 | Caldesmonina | E89 lub h-CD | 40 |  |  |  |  |
| 39 | CD56 | MRQ-42 lub123C3 | 200 |  |  |  |  |
| 40 | CK HMW | 34βE12 | 200 |  |  |  |  |
| 41 | TdT | Polyclonal | 40 |  |  |  |  |
| 42 | GCDFP -15 | EP1582Y LUB 23a3 | 40 |  |  |  |  |
| 43 | CDX 2 | EPR 2764Y lub DAK-CDX2 | 40 |  |  |  |  |
| 44 | P 63 | 4A4 LUB DAKp-63 | 450 |  |  |  |  |
| 45 | Androgen receptor | SP107 lub AR441 | 40 |  |  |  |  |
| 46 | Renal Cell Carcinoma | PN-15 lub SPM314 | 40 |  |  |  |  |
| 47 | Podoplanina | D2-40 | 40 |  |  |  |  |
| 48 | Calponina1 | EP798Ylub CALP | 250 |  |  |  |  |
| 49 | P 53 | DO-7 lub BP53-11 | 150 |  |  |  |  |
| 50 | PAX 5 | SP34 LUB DAK-5 | 100 |  |  |  |  |
| 51 | PAX 8 | MRQ-50 | 150 |  |  |  |  |
| 52 | HER 2 | 4B5 | 1800 |  |  |  |  |
| 53 | EGFR | 5B7 lub dowolny | 50 |  |  |  |  |
| 54 | HEP PAR | dowolny | 50 |  |  |  |  |
| 55 | Napsin | MRQ-60 lub dowolny | 50 |  |  |  |  |
| 56 | P 16 | E6H4 lub dowolny | 120 |  |  |  |  |
| 57 | GFAP | Polyclonal lub EP672Y | 40 |  |  |  |  |
| 58 | Melanoma Triple Coctail | HMB45+A103+T311 | 120 |  |  |  |  |
| 59 | Beta-catenin | β Catenin 1 lub 14  | 50 |  |  |  |  |
| 60 | HHV-8 | 13B10 lub dowolny | 40 |  |  |  |  |
| 61 | Helikobacter Pylori | SP48 lub Polyclonal | 40 |  |  |  |  |
| 62 | ZAP-70 | 2F3.2 | 40 |  |  |  |  |
| 63 | ARGINASE 1 | SP156 lub dowolny | 40 |  |  |  |  |
| 64 | Glipikan-3 | dowolny | 40 |  |  |  |  |
| 65 | IgG4 | MRQ-44 lub Poliklonal | 40 |  |  |  |  |
| 66 | A-1- Antitripsin (AAT) | Polyclonal lub dowolny | 40 |  |  |  |  |
| 67 | BOB.1 | Dak -pax 5 lub SP 92 | 40 |  |  |  |  |
| 68 | Epithelial Related Antigen | MOC - 31 | 40 |  |  |  |  |
| 69 | DOG | SP31 LUB DOWOLNY | 40 |  |  |  |  |
| 70 | Galectin-3 | 9C4 LUB DOWOLNY | 40 |  |  |  |  |
| 71 | MESOTHELIAL CELL | HBME-1 | 40 |  |  |  |  |
| 72 | Glycophorin A | Glycophorin A lub GA-R2 | 200 |  |  |  |  |
| 73 | CD 1a | EP 3622 lub O 10 | 50 |  |  |  |  |
| 74 | CD 2 | MRQ-11 lub AB75 | 80 |  |  |  |  |
| 75 | CK 14 | SP 53 lub dowolny | 40 |  |  |  |  |
| 76 | c-MYC | dowolny | 40 |  |  |  |  |
| 77 | GATA-3 | L50-823 lub dowolny | 40 |  |  |  |  |
| 78 | hPL | Polyclonal lub dowolny | 40 |  |  |  |  |
| 79 | KAPPA | Polyclonal | 250 |  |  |  |  |
| 80 | LAMBDA | Polyclonal | 250 |  |  |  |  |
| 81 | MLH -1 | M1 lub dowolny | 40 |  |  |  |  |
| 82 | MUC 6 | MRQ-20 lub dowolny | 40 |  |  |  |  |
| 83 | p-120 | 98 lub dowolny | 40 |  |  |  |  |
| 84 | SALL4 | .6E3 lub dowolny | 40 |  |  |  |  |
| 85 | .SOX-2 | 16/15 lub dowolny | 40 |  |  |  |  |
| 86 | Claudin 1 | dowolny | 40 |  |  |  |  |
| 87 | MUC 4 | dowolny | 40 |  |  |  |  |
| 88 | MITF | dowolny | 40 |  |  |  |  |
| 89 | PAX 2 | dowolny | 40 |  |  |  |  |
| 90 | pTEN | dowolny | 40 |  |  |  |  |
| 91 | OCT4 | dowolny | 40 |  |  |  |  |
| 92 | CD 15 | Carb-3 lub dowolny | 250 |  |  |  |  |
| 93 | CD 138 | MI 15 lub dowolny | 250 |  |  |  |  |
| 94 | Cathepsin K | dowolny | 40 |  |  |  |  |
| 95 | CD 44 | dowolny | 40 |  |  |  |  |
| 96 | CD 57 | TB01 lub NK-1 | 40 |  |  |  |  |
| 97 | OCT-2 | dowolny | 40 |  |  |  |  |
| 98 | CD 68 | KP1 | 100 |  |  |  |  |
| 99 | EMA | E29 | 200 |  |  |  |  |
| 100 | PSA | Poliklonal, lub ER-PR8 | 100 |  |  |  |  |
| 101 | CZ VIII- WILLBRAND | Polyclonal | 150 |  |  |  |  |
| 102 | SYNAPTOPHYZIN | Dak-synap,lub dowolny | 120 |  |  |  |  |
| 103 | CD 99 | 12E7RTU,lub 013 | 50 |  |  |  |  |
| 104 | CD 43 | DF-T1, lub L60 | 40 |  |  |  |  |
| 105 | CD 31 | JC70A | 40 |  |  |  |  |
| 106 | MYOSINA | SMMS-1 | 40 |  |  |  |  |
| 107 | TTF 1 | 8G7G3/1 | 150 |  |  |  |  |
| 108 | CD 79 a | JCB117,lub SP 18 | 40 |  |  |  |  |
| 109 | CD4 | 4B12, lub SP 35 | 80 |  |  |  |  |
| 110 | WT-1 | 6F-H2 | 80 |  |  |  |  |
| 111 | CK 8&18 | DC10, lubB22.1&B23.1 | 40 |  |  |  |  |
| 112 | Ca 125 | M11,lub OC125 | 40 |  |  |  |  |
| 113 | AFP | Polyclonal | 40 |  |  |  |  |
| 114 | MUM 1 | MUM 1p,lub MRQ-43 | 120 |  |  |  |  |
| 115 | Myo D1 | 5.8A, lub EP212 | 40 |  |  |  |  |
| 116 | AMACR | 13H4, lub dowolny | 500 |  |  |  |  |
| 117 | CD7 | CBC.37lub SP 94 | 40 |  |  |  |  |
| 118 | CD8 | C8/144B, lub SP 57 | 40 |  |  |  |  |
| 119 | CK 17 | E3,lub SP 95 | 40 |  |  |  |  |
| 120 | B hCG | Polyclonal | 40 |  |  |  |  |
| 121 | Inhibin alpha | R1 | 40 |  |  |  |  |
| 122 | Mast Cell Tryptase | AA1 lub G3 | 40 |  |  |  |  |
| 123 | NSE | BBS/NC/VI-H14, lub MRQ-55 | 40 |  |  |  |  |
| 124 | EBSZTAIN BAR | CS.1-4 | 120 |  |  |  |  |
| 125 | MUC5AC | CLH2, lub MRQ-19 | 40 |  |  |  |  |
| 126 | MUC2 | CCP58, ub MRQ-18 | 40 |  |  |  |  |
| 127 | AMYLOID A | mc1 | 40 |  |  |  |  |
| 128 | CEA | CEA 31 | 40 |  |  |  |  |
| 129 | Tyrosinase | T311 | 40 |  |  |  |  |
| 130 | CK MNF 116 | dowolny | 40 |  |  |  |  |
| 131 | CAM 5,2 | dowolny | 40 |  |  |  |  |
| 132 | SOX 10\* | dowolny | 50 |  |  |  |  |
| 133 | ERG | EPR 3864 | 50 |  |  |  |  |
| 134 | CD 163 | MRQ-26 | 50 |  |  |  |  |
| 135 | NKI C3 | dowolny | 50 |  |  |  |  |
| 136 | FLI 1 | dowolny | 50 |  |  |  |  |
| 137 | INI - 1 | MRQ-27 | 50 |  |  |  |  |
| 138 | BAP-1 | dowolny | 50 |  |  |  |  |
| 139 | P40 | BC28 | 50 |  |  |  |  |
| 140 | PD-L1 | dowolny | 50 |  |  |  |  |
| 141 |  |  | 25650 | Wartość ogółem |  |  |  |

W sytuacji, gdy nie jest możliwa dostawa dokładnej ilości zapotrzebowanych odczynników z uwagi na sposób ich konfekcjonowania u wykonawców, Zamawiający dopuszcza modyfikację ich ilości przy zastosowaniu zasady zaokrąglenia w górę tj. kalkulacji takiej ilości sztuk (opakowań ), którą zamawiający będzie musiał zakupić, aby zostało zrealizowane jego zaopatrzenie, przy założeniu pewnej nadwyżki.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Tabela A2** |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |
|  |  |  |  |  |  |
|  |
|  | **Tabela A2**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Numer katalogowy\* | Komplet odczynników; kontrole; szkiełka; naklejki kodów itp.) umożliwiający wykonanie Min. 25650 oznaczeń \* | Ilość oznaczeń z opakowania\* | ILOŚĆ OPAK | CENA JEDN. BRUTTO OPAK. | WARTOŚĆ BRUTTO |
| 1 |  |  |  |  |  |  |
| 2 |  |  |  |  |  |  |
| 3 |  |  |  |  |  |  |
| 4 |  |  |  |  |  |  |
| 5 |  |  |  |  |  |  |
| 6 |  |  |  |  |  |  |
| **Razem** |  |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Wymagania:** |  |  |  |  |  |
| Wykonawca w formularzu powinien wskazać asortyment wystarczający do wykonania 25 650 oznaczeń w ciągu 24 miesięcy przeznaczony dla skrawków parafinowych, mrożaków, rozmazów, cytospinów, szpiku kostnego, bioptatów podanej w tabeli A1 ilości testów przy użyciu sprzętu opisanego w tabeli B. |
|  |  |  |  |  |  |
| Wykonawca musi oszacować ilość opakowań do ilości oznaczeń zawyżając do pełnej ilości |
| opakowań. |  |  |  |  |  |

 |  |  |  |  |
|  |  |  |  |  |  |
|  | **Tabela B**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Lp. | Nazwa aparatu/producent/rok produkcji | Ilość miesięcy | Dzierżawa brutto (zł/miesiąc) \* | Wartość brutto (zł) za 24 m-ce \* |
|  |  | 24 |  |  |
|  |  | 24 |  |  |
|  |  |  |  |  |

 |  |  |  |  |
|  |  |  |  |  |  |
| \*- uzupełnić |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  | **Razem wartość brutto:** |  |  |  |
|  |  |  |  |  |  |
|  | Wartość brutto tabeli A1+wartość brutto tabeli A2 + Wartość brutto Tabeli B |
|  | Wartość brutto należy wpisać do formularza ofertowego Załącznik nr 4 |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  | **Termin dostaw cząstkowych:……………………………..\*** |  |
|  |
|  |  |  |  |  |  |
|  | \*- wpisuje wykonawca |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  | ................................................................ |  |  |  |  |
|  | podpis osoby upoważnionej |  |  |  |
|  | do reprezentacji Wykonawcy |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |  |